earnings
confidence high
sentiment positive
materiality 0.75
Adial reports FDA agreement on Phase 3 design for AD04; Q2 net loss $2.0M, cash $5.9M
ADIAL PHARMACEUTICALS, INC.
2025-Q2 EPS
reported -$0.49
vs consensus -$6.38
▲ beat
(+92.3%)
- Completed End of Phase 2 meeting with FDA; agreement on key Phase 3 protocol elements for AD04 in Alcohol Use Disorder.
- Cash and equivalents $5.9M as of June 30, 2025 (up from $2.4M at March 31); cash runway into Q2 2026.
- Public offering closed June 17, 2025 raised net proceeds ~$3.0M from 11.1M shares and warrants at $0.3251.
- Entered manufacturing agreements with Thermo Fisher Scientific and Cambrex for AD04 drug product and substance.
- Regained Nasdaq compliance on July 14, 2025 for minimum stockholders' equity of $2.5M.
item 2.02item 9.01